Patients undergo first doses of GE HealthCare's PET radiotracer Flyrcado (flurpiridaz F 18) injection at early adopter sites ...

GE HealthCare (GEHC) has delivered the first patient doses of Flyrcado or flurpiridaz F 18 njection, a first-of-its-kind unit dose positron ...

GE HealthCare has delivered the initial subject doses of Flyrcado (flurpiridaz F 18) injection, for coronary artery disease ...

Discover GE HealthCare's Q4 2024 insights: record $19.8B backlog, 18.7% margin growth, and Flyrcado's 2025 launch.

February 13, 2025GE HealthCare Technologies Inc. beats earnings expectations. Reported EPS is $1.45, expectations were $1.26.

The largest life sciences association in the state recognized those driving discovery during its 32nd annual dinner meeting ...

Good day, and thank you for standing by. Welcome to the GE HealthCare fourth quarter and full year 2024 earnings conference call. (Operator Instructions) Please be advised this conference is being ...

September 2024: The U.S. Food and Drug Administration cleared GE HealthCare's diagnostic medicine, Flyrcado, to detect coronary artery disease through PET myocardial perfusion imaging. Flyrcado ...

For example, our cath lab, Allia IGS Pulse is outperforming our expectations and we're on track to launch Flyrcado in the near term. We continued to advance our leadership position in AI.